Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 1.93 USD -5.85%
Market Cap: 85.4m USD
Have any thoughts about
Adagene Inc?
Write Note

Adagene Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adagene Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Adagene Inc
NASDAQ:ADAG
Income from Continuing Operations
-$18.9m
CAGR 3-Years
24%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Income from Continuing Operations
-ÂĄ6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Income from Continuing Operations
-ÂĄ1.3B
CAGR 3-Years
3%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Income from Continuing Operations
ÂĄ1.2B
CAGR 3-Years
22%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Income from Continuing Operations
ÂĄ3.7B
CAGR 3-Years
-26%
CAGR 5-Years
12%
CAGR 10-Years
39%
Imeik Technology Development Co Ltd
SZSE:300896
Income from Continuing Operations
ÂĄ1.9B
CAGR 3-Years
62%
CAGR 5-Years
74%
CAGR 10-Years
N/A
No Stocks Found

Adagene Inc
Glance View

Market Cap
85.4m USD
Industry
Biotechnology

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG Intrinsic Value
0.96 USD
Overvaluation 50%
Intrinsic Value
Price

See Also

What is Adagene Inc's Income from Continuing Operations?
Income from Continuing Operations
-18.9m USD

Based on the financial report for Dec 31, 2023, Adagene Inc's Income from Continuing Operations amounts to -18.9m USD.

What is Adagene Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-4%

Over the last year, the Income from Continuing Operations growth was 76%. The average annual Income from Continuing Operations growth rates for Adagene Inc have been 24% over the past three years , -4% over the past five years .

Back to Top